A double blind, randomized, placebo-controlled, crossover, outpatient trial of amifampridine phosphate for patients with MuSK-antibody positive myasthenia gravis

Trial Profile

A double blind, randomized, placebo-controlled, crossover, outpatient trial of amifampridine phosphate for patients with MuSK-antibody positive myasthenia gravis

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Amifampridine (Primary)
  • Indications Myasthenia gravis
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 09 Aug 2017 According to a Catalyst Pharmaceuticals media release, data was presented at the 13th International Conference on Myasthenia Gravis and Related Disorders in May, 2017.
    • 09 Aug 2017 Status changed from recruiting to completed, according to a Catalyst Pharmaceutical media release.
    • 15 Mar 2017 According to a Catalyst Pharmaceuticals media release, data will be presented at the 13th International Conference on Myasthenia Gravis and Related Disorders in May, 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top